When the going gets tough
Joe Miletich tells NGP why it’s more important than ever for pharmaceutical R&D to pursue the highest levels of innovation.
A Bright Outlook
Natalie Brandweiner talks to Lilly’s William Chin about personalized medicine, partnerships, and using the company’s PD2 initiative is generate new compounds.
Up Close and Personal
Reinventing big pharma’s corporate image has been pivotal in EMD Serono’s personalized approach. President and CEO Fereydoun Firouz tells NGP’s Natalie Brandweiner about the company’s drive to innovate, its community spirit, and its participation in the conversations around healthcare reform in the United States.
Golden Age of Discovery
Martin Mackay, Pfizer’s President of Global R&D, explains how in the age of tailored therapies, the end of diseases is in sight, and how the merger with Wyeth will set the company at the forefront of drug discovery.
Made to Measure
With pipelines running dry and fortunes flagging, the pharmaceutical industry is casting about for a savior. Could individually tailored treatments be the answer? By Marie Shields